TRIALSITEIQ PUBLIC FEASIBILITY SCORECARD · GRADE C

NCT07777861: A Randomized, Double-Masked, Placebo-Controlled Phase II Clinical Trial Evaluating the Efficacy and Safety of G01 Eye Drops in the Treatment of Optic Nerve Injury Associated With Open-Angle Glaucoma

Sponsor: Qingdao WanMing BioCell Pharmaceutics Co.,Ltd. · Phase: PHASE2 · Area: CARDIOLOGY_METABOLIC · Target Enrollment: 90 pts

Competing Trials Overlap

2 Active Trials

Excess Burn Exposure

$6,905,600

Rescue Site Savings

+$4,548,400

Unlock Full NCT07777861 Backup Super-Site Packet ($49 One-Time Pass)

Download the complete list of top-decile low-cannibalization clinical sites, verified Principal Investigator (PI) direct emails/phones, and protocol optimization benchmarks.

Download $49 NCT07777861 Rescue Dossier →